<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高级期刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=202 31114050918&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc =20230708114047<description>心血管高分期刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231114050918&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc=20230708114047" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 11 月 14 日星期二 10:09:21 +0000</lastbuilddate><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title>缺血试验中冠状动脉血运重建模式的结果</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956961/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff= 20231114050918&amp;v=2.17.9.post6+86293ac<description>结论：在缺血中，与 CON 相比，通过 PCI 和 CABG 进行早期血运重建与较高的早期心血管事件风险和较低的长期心血管事件风险相关。由于方案定义的程序性心梗，CABG 后的早期风险最大。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol。 2023 年 11 月 8 日：S0735-1097(23)07988-3。 doi：10.1016/j.jacc.2023.11.002。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：在 ISCHEMIA 试验中，采用血管造影和经皮 (PCI) 或手术 (CABG) 冠状动脉血运重建的侵入性 (INV) 策略与保守 (CON) 策略治疗的稳定型冠状动脉疾病患者发生缺血事件的风险相似的初始药物治疗。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：分别分析接受 PCI 或 CABG 治疗的 INV 患者的结局。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：之前没有主要结局事件的患者从血运重建时起被分类为 INV-PCI 或 INV-CABG。使用 ISCHEMIA 主要结局（心血管死亡、方案定义的心肌梗死 (MI) 或因不稳定心绞痛住院、心力衰竭或复苏性心脏骤停的综合结果）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 INV-CABG 患者中，中位随访 2.85 年时，84/512 例 (16.4%) 发生主要结局事件； 48 起事件 (57.1%) 发生在 CABG 后 30 天内，其中包括 40 起手术性 MI；在 INV-PCI 患者中，中位随访时间为 2.94 年时，主要结局事件发生率为 147/1500 (9.8%)；其中 31 例 (21.1%) 发生在 PCI 术后 30 天内，其中 23 例为手术性 MI。相比之下，352/2591 (13.6%) 例 CON 患者在中位随访 3.2 年时出现主要结局事件，其中 22 例 (6.3%) 在随机分组后 30 天内发生。 CABG 和 PCI 后 30 天内调整后的主要结局风险 (HR [95%CI]) 较高 (16.25 (11.44-23.07) 和 2.99 (1.97-4.53))，此后较低 (0.63 (0.44-0.89) 和 0.66) (0.53-0.82))。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在缺血中，与 CON 相比，通过 PCI 和 CABG 进行早期血运重建与较高的早期心血管事件风险和较低的长期心血管事件风险相关。由于方案定义的程序性心梗，CABG 后的早期风险最大。</p><p style="color: lightgray">电话号码： <a href="https://pubmed.ncbi.nlm.nih.gov/37956961/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114050918&v=2.17.9.post6+86293ac">37956961</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.11.002>10.1016/j.jacc.2023.11.002</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956961</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>比约恩·雷德福斯</dc:creator><dc:creator>格雷格·W·斯通</dc:creator><dc:creator>约翰·H·亚历山大</dc:creator><dc:creator>埃里克·R·贝茨</dc:creator><dc:creator>迪帕克·巴特</dc:creator><dc:creator>朱塞佩·比昂迪·佐卡伊</dc:creator><dc:creator>图利奥·卡尔多纳佐</dc:creator><dc:creator>迈克尔·法库</dc:creator><dc:creator>穆罕默德·拉胡马</dc:creator><dc:creator>约翰·普斯卡什</dc:creator><dc:creator>西格丽德·桑德纳</dc:creator><dc:creator>马里奥·弗尔·高迪诺</dc:creator><dc:date>2023-11-13</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>缺血试验中冠状动脉血运重建模式的结果</dc:title><dc:identifier>下午:37956961</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.11.002</dc:identifier></item><item><title>动态心电图变化是心源性猝死的新风险标志</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956651/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff= 20231114050918&amp;v=2.17.9.post6+86293ac<description>结论：动态心电图重构改善了 SCD 风险预测，超越了临床因素与静态心电图相结合的结果，并在不同地理位置的人群中成功进行了验证。这些发现引入了 SCD 动态风险的新概念，值得进一步详细研究。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> 《欧洲心脏杂志》2023 年 11 月 13 日：ehad770。 doi：10.1093/eurheartj/ehad770。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：心电图异常已被评估为心源性猝死（SCD）的静态风险标志，但动态心电图重塑的潜在重要性尚未得到研究。在这项研究中，研究了最终患有 SCD 的个体动态心电图重塑的性质和患病率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：研究人群选自美国俄勒冈州（2002 年，发现队列）和美国加利福尼亚州（2015 年，验证队列）的两项前瞻性社区 SCD 研究。在本次研究中，确定了 231 个发现病例（2015-2017 年）和 203 个验证病例（2015-2021 年），具有 ≥2 个存档的 SCD 前心电图，并根据年龄、性别与 234 个发现病例和 203 个验证对照相匹配。和心电图之间的持续时间。动态心电图重塑是根据先前验证的累积 6 变量心电图电风险评分 (ERS) 的进展来衡量的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：俄勒冈州 SCD 病例与对照组相比，随着时间的推移，ERS 增加更大[+1.06（95% CI +0.89 至 +1.24）vs.-0.05（-0.21 至 +0.11）； p &lt; 0.001]。这些发现在加利福尼亚州被成功复制[+0.87（+0.7至+1.04）对比-0.11（-0.27至0.05）； p &lt; 0.001]。在多变量模型中，异常动态心电图重塑改善了俄勒冈州相对于基线心电图、人口统计学和临床​​ SCD 危险因素的 SCD 预测 [AUC 0.770 (95% CI 0.727-0.812) 增加至 AUC 0.869 (95% CI 0.837-0.902)] 和加州队列。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：动态心电图重构改善了 SCD 风险预测，超越了临床因素与静态心电图相结合的结果，并在不同地理位置的人群中成功进行了验证。这些发现引入了 SCD 动态风险的新概念，值得进一步详细研究。</p><p style="color: lightgray">电话号码： <a href="https://pubmed.ncbi.nlm.nih.gov/37956651/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114050918&v=2.17.9.post6+86293ac">37956651</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad770>10.1093/eurheartj/ehad770</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956651</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>范汉恩</dc:creator><dc:creator>霍尔姆斯特罗姆</dc:creator><dc:creator>H楚格</dc:creator><dc:creator>乌伊·埃瓦纳多</dc:creator><dc:creator>K中村</dc:creator><dc:creator>张正</dc:creator><dc:creator>萨尔武奇</dc:creator><dc:creator>J瑞</dc:creator><dc:creator>K雷尼尔</dc:creator><dc:creator>党卫军楚格</dc:creator><dc:date>2023-11-13</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>动态心电图变化是心源性猝死的新风险标志</dc:title><dc:identifier>下午:37956651</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad770</dc:identifier></item><item><title>破坏细胞特异性 miRNA-CXCR4 相互作用对小鼠具有动脉粥样硬化保护作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/37957335/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff= 20231114050918&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;">纳特·Rev Cardiol。 2023 年 11 月 13 日。doi：10.1038/s41569-023-00959-y。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">电话号码： <a href="https://pubmed.ncbi.nlm.nih.gov/37957335/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114050918&v=2.17.9.post6+86293ac">37957335</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00959-y>10.1038/s41569-023-00959-y</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37957335</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>艾琳·费尔南德斯-鲁伊斯</dc:creator><dc:date>2023-11-13</dc:date><dc:source>自然评论。心脏病学</dc:source><dc:title>破坏细胞特异性 miRNA-CXCR4 相互作用对小鼠具有动脉粥样硬化保护作用</dc:title><dc:identifier>下午:37957335</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00959-y</dc:identifier></item><item><title>长房性高频率发作≥24小时的患者使用艾多沙班抗凝</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956458/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff= 20231114050918&amp;v=2.17.9.post6+86293ac<description>结论：对于设备检测到的 AHRE 和卒中危险因素的患者，这项假设生成分析并未发现 AHRE 持续时间与抗凝治疗之间存在相互作用。需要进一步研究来识别具有高中风风险的长 AHRE 患者。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> 《欧洲心脏杂志》2023 年 11 月 12 日：ehad771。 doi：10.1093/eurheartj/ehad771。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：长期心房高频率发作（AHRE）≥24小时且有卒中危险因素的患者通常接受抗凝治疗以预防卒中。从未将这些患者的抗凝治疗与不抗凝治疗进行比较。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：NOAH-AFNET 6 的二次预先指定分析检查了 AHRE 患者基线 AHRE 持续时间与艾多沙班抗凝治疗与安慰剂相比的相互作用以及中风危险因素。主要疗效结局是卒中、全身性栓塞或心血管死亡的复合结局。安全性结果是大出血和死亡的综合结果。关键的次要结局是这些结局和心电图诊断的房颤的组成部分。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：纳入 NOAH-AFNET 6 的 259/2389 名患者在基线时存在 AHRE ≥24 小时（11%，78 ± 7 岁，28% 女性，CHA2DS2-VASc 评分 4）。临床特征与 AHRE 较短的患者没有差异。在中位随访 1.8 年期间，主要结局发生在接受抗凝治疗的 9/132 名 AHRE ≥24 小时患者（4.3%/患者年，2 次中风）和 14/127 名接受安慰剂治疗的患者（6.9%）。 /患者年，2 次中风）。 AHRE 持续时间与抗凝治疗的疗效（p 相互作用 = 0.65）或安全性（p 相互作用 = 0.98）没有相互作用。包括 AHRE 作为连续参数的分析证实了这一点。 AHRE ≥24 小时的患者比 AHRE 较短的患者（8.2%/患者年；p &lt; 0.001）发生更多心电图诊断的房颤（17.0%/患者年）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：对于设备检测到的 AHRE 和卒中危险因素的患者，这项假设生成分析并未发现 AHRE 持续时间与抗凝治疗之间存在相互作用。需要进一步研究来识别具有高中风风险的长 AHRE 患者。</p><p style="color: lightgray">电话号码： <a href="https://pubmed.ncbi.nlm.nih.gov/37956458/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114050918&v=2.17.9.post6+86293ac">37956458</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad771>10.1093/eurheartj/ehad771</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956458</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>尼娜·贝歇尔</dc:creator><dc:creator>托比亚斯·托尼斯</dc:creator><dc:creator>埃马努埃莱·贝尔塔利亚</dc:creator><dc:creator>卡琳娜·布洛姆斯特罗姆-伦奎斯特</dc:creator><dc:creator>阿克塞尔·布兰德斯</dc:creator><dc:creator>努诺·卡巴内拉斯</dc:creator><dc:creator>梅兰妮·卡尔弗特</dc:creator><dc:creator>约翰·卡姆</dc:creator><dc:creator>格雷戈里·克卢韦拉基斯</dc:creator><dc:creator>格奥尔基·安德烈·丹</dc:creator><dc:creator>沃尔夫冈·迪希特尔</dc:creator><dc:creator>汉斯·克里斯托夫·迪纳</dc:creator><dc:creator>亚历山大·费伦茨</dc:creator><dc:creator>安德烈亚斯·戈特</dc:creator><dc:creator>乔里斯·R·德·格鲁特</dc:creator><dc:creator>阿斯特丽德·赫尔曼斯</dc:creator><dc:creator>格雷戈里·YH·利普</dc:creator><dc:creator>安德烈·卢宾斯基</dc:creator><dc:creator>埃洛伊·马里琼</dc:creator><dc:creator>贝拉·默克利</dc:creator><dc:creator>路易斯·蒙</dc:creator><dc:creator>安-凯瑟琳·奥兹加</dc:creator><dc:creator>金·拉贾潘</dc:creator><dc:creator>安德烈·萨科齐</dc:creator><dc:creator>丹尼尔·谢尔</dc:creator><dc:creator>雷纳特·B·施纳贝尔</dc:creator><dc:creator>乌尔里希·肖顿</dc:creator><dc:creator>苏珊·塞纳</dc:creator><dc:creator>伊曼纽尔·西曼蒂拉基斯</dc:creator><dc:creator>帕诺斯·瓦尔达斯</dc:creator><dc:creator>瓦西尔·维尔切夫</dc:creator><dc:creator>丹·威克特尔</dc:creator><dc:creator>安东尼娅·扎普夫</dc:creator><dc:creator>保卢斯·基希霍夫</dc:creator><dc:date>2023-11-13</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>长房性高频率发作≥24小时的患者使用艾多沙班抗凝</dc:title><dc:identifier>下午:37956458</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad771</dc:identifier></item><item><title>更正：2020 ACC/AHA 瓣膜性心脏病患者管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会的报告</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956227/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff= 20231114050918&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。 2023 年 11 月 14 日；148(20):e185。 doi：10.1161/CIR.0000000000001190。电子版 2023 年 11 月 13 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956227/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114050918&v=2.17.9.post6+86293ac">37956227</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001190>10.1161/CIR.0000000000001190</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956227</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:date> 2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>更正：2020 ACC/AHA 瓣膜性心脏病患者管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会的报告</dc:title><dc:identifier>下午:37956227</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001190</dc:identifier></item><item><title>布鲁格达综合症的风险分层：我们能降到多低？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37956226/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff= 20231114050918&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。 2023 年 11 月 14 日；148(20):1556-1558。 doi：10.1161/CIRCULATIONAHA.123.066697。电子版 2023 年 11 月 13 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956226/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114050918&v=2.17.9.post6+86293ac">37956226</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066697>10.1161/循环AHA.123.066697</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956226</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>阿瑟·王尔德</dc:creator><dc:creator>约翰·赛南</dc:creator><dc:date>2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>布鲁格达综合症的风险分层：我们能降到多低？</dc:title><dc:identifier>下午:37956226</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066697</dc:identifier></item><item><title>张等人关于文章“多梳蛋白 CBX7 通过调节 TARDBP/RBM38 轴抑制心肌细胞增殖”的信函</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956225/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff= 20231114050918&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。 2023 年 11 月 14 日；148(20):1602-1603。 doi：10.1161/CIRCULATIONAHA.123.066427。电子版 2023 年 11 月 13 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956225/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114050918&v=2.17.9.post6+86293ac">37956225</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066427>10.1161/循环AHA.123.066427</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956225</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>张曼如</dc:creator><dc:creator>郭丹丹</dc:creator><dc:creator>赵晶</dc:creator><dc:date>2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>张等人关于文章“多梳蛋白 CBX7 通过调节 TARDBP/RBM38 轴抑制心肌细胞增殖”的信函</dc:title><dc:identifier>下午:37956225</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066427</dc:identifier></item><item><title> Cho 和 Yoon 对有关文章“Polycomb 组蛋白 CBX7 通过调节 TARDBP/RBM38 轴抑制心肌细胞增殖”的信件的回应</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956224/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff= 20231114050918&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。 2023 年 11 月 14 日；148(20):1604-1605。 doi：10.1161/CIRCULATIONAHA.123.066624。电子版 2023 年 11 月 13 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956224/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114050918&v=2.17.9.post6+86293ac">37956224</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066624>10.1161/循环AHA.123.066624</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956224</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>曹圭元</dc:creator><dc:creator>尹英燮</dc:creator><dc:date>2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>Cho 和 Yoon 对有关文章“Polycomb 组蛋白 CBX7 通过调节 TARDBP/RBM38 轴抑制心肌细胞增殖”的信件的回应</dc:title><dc:identifier>下午:37956224</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066624</dc:identifier></item><item><title>使用患者来源的诱导多能干细胞研究由 &lt;em>;NAA10&lt;/em>; 遗传变异引起的长 QT 综合征</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956223/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff= 20231114050918&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。 2023 年 11 月 14 日；148(20):1598-1601。 doi：10.1161/CIRCULATIONAHA.122.061864。电子版 2023 年 11 月 13 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956223/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114050918&v=2.17.9.post6+86293ac">37956223</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.061864>10.1161/流通AHA.122.061864</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956223</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>纳吉特·贝尔巴奇尔</dc:creator><dc:creator>吴一阳</dc:creator><dc:creator>沉梦成</dc:creator><dc:creator>张索菲亚·L</dc:creator><dc:creator>张乔</dc:creator><dc:creator>刘春</dc:creator><dc:creator>比约恩·C·诺尔曼</dc:creator><dc:creator>戈尔森·里昂</dc:creator><dc:creator>马宁</dc:creator><dc:creator>约瑟夫·吴</dc:creator><dc:date>2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>使用患者来源的诱导多能干细胞研究由 &lt;em>;NAA10&lt;/em>; 遗传变异引起的长 QT 综合征</dc:title><dc:identifier>下午:37956223</dc:identifier><dc:identifier> doi:10.1161/循环AHA.122.061864</dc:identifier></item><item><title> &lt;em>;流通&lt;/em>;系列期刊的亮点</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956222/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff= 20231114050918&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。 2023 年 11 月 14 日；148(20):1593-1597。 doi：10.1161/CIRCULATIONAHA.123.067572。电子版 2023 年 11 月 13 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956222/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114050918&v=2.17.9.post6+86293ac">37956222</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067572>10.1161/流通AHA.123.067572</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956222</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:date> 2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>&lt;em>;流通&lt;/em>;系列期刊的亮点</dc:title><dc:identifier>下午:37956222</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.067572</dc:identifier></item><item><title>艾多沙班治疗慢性血栓栓塞性肺动脉高压患者的多中心、单盲、随机、华法林对照试验：KABUKI 试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956127/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff= 20231114050918&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。 2023 年 11 月 13 日。doi：10.1161/CIRCULATIONAHA.123.067528。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956127/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114050918&v=2.17.9.post6+86293ac">37956127</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067528>10.1161/流通AHA.123.067528</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956127</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>细川一也</dc:creator><dc:creator>渡边弘子</dc:creator><dc:creator>谷口佑</dc:creator><dc:creator>池田信隆</dc:creator><dc:creator>稻波匠美</dc:creator><dc:creator>安田聪</dc:creator><dc:creator>室原丰明</dc:creator><dc:creator>波多野胜</dc:creator><dc:creator>田村雄一</dc:creator><dc:creator>山下淳</dc:creator><dc:creator>辰巳光一郎</dc:creator><dc:creator>辻野一三</dc:creator><dc:creator>小早川优子</dc:creator><dc:creator>安达四郎</dc:creator><dc:creator>矢板信宏</dc:creator><dc:creator>水月俊</dc:creator><dc:creator>户高浩二</dc:creator><dc:creator>福田敬一</dc:creator><dc:creator>筒井宏之</dc:creator><dc:creator>阿部光太郎</dc:creator><dc:creator>歌舞伎调查员</dc:creator><dc:date>2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>艾多沙班治疗慢性血栓栓塞性肺动脉高压患者的多中心、单盲、随机、华法林对照试验：KABUKI 试验</dc:title><dc:identifier>下午：37956127</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.067528</dc:identifier></item><item><title>托塞米与呋塞米在新发慢性心力衰竭患者与恶化慢性心力衰竭患者中的​​比较：TRANSFORM-HF 随机临床试验的子研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37955908/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff= 20231114050918&amp;v=2.17.9.post6+86293ac<description>结论和相关性：在因心力衰竭住院后出院的患者中，与 WHF 相比，新发心力衰竭具有更好的临床和患者报告结果。无论心衰类型如何，托拉塞米和呋塞米在 12 个月的临床或患者报告的结果方面没有显着差异。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA 心脏。 2023 年 11 月 13 日。doi：10.1001/jamacardio.2023.4776。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：新发心力衰竭 (HF) 和慢性心力衰竭 (WHF) 恶化患者之间的临床特征、结局和利尿治疗效果可能存在差异。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：比较托拉塞米与呋塞米在因新发心衰与 WHF 住院患者中的临床特征和治疗结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、环境和参与者：所有记录有射血分数的患者均被随机参加托拉塞米与呋塞米治疗心力衰竭的比较 (TRANSFORM-HF) 试验（该试验于 6 月 18 日至 2022 年 3 月期间进行），均纳入本次事后分析。研究数据是在 2023 年 3 月至 5 月期间进行分析的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">暴露：患者根据心力衰竭类型进行分类，并根据袢利尿策略进一步分类。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和指标：终点包括 12 个月内的全因死亡率和住院结果，以及堪萨斯城心肌病问卷临床总结评分 (KCCQ-CSS) 相对于基线的变化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 2858 名患者（平均 [SD] 年龄，64.5 [14.0] 岁；1803 名男性 [63.1%]）中，838 名患者（29.3%）患有新发心衰，2020 名患者（70.7%）患有 WHF。新发心力衰竭患者较年轻（平均 [SD] 年龄，60.6 [14.5] 岁 vs 66.1 [13.5] 岁），肾小球滤过率较高（平均 [SD]，68.6 [24.9] vs 57.0 [24.0]），利钠肽水平较低（中位[IQR]，脑型利尿肽，855.0 [423.0-1555.0] pg/mL vs 1022.0 [500.0-1927.0] pg/mL），并且倾向于在较低剂量的袢利尿剂中排出（平均 [SD]，50.3 [46.2] 毫克 vs 63.8 [52.4] 毫克）。新发 HF 与 12 个月时较低的全因死亡率相关（新发 838 例中的 65 例 [9.1%] 对比 2020 年 WHF，408 例 [25.4%]；调整后的风险比 [aHR]，0.50；95% CI，0.38 -0.66；P &lt; .001)。同样，在新发心力衰竭患者中，12 个月时全因首次再住院率较低，12 个月时 KCCQ-CSS 较基线有较大改善（中位 [IQR]：新发 29.94 [27.35-32.54] 对比 WHF，23.68） [21.62-25.74]；调整后估计平均值差异：6.26；95% CI，3.72-8.81；P &lt; .001）。托拉塞米与呋塞米两种治疗的死亡率均无显着差异（事件数[每 100 名患者年的发生率]：托拉塞米，27 [7.4%] vs 呋塞米，38 [10.9%]；aHR，0.70；95 % CI，0.40-1.14；P = .15）或 WHF（托塞米 212 [26.8%] 与呋塞米，196 [24.0%]；aHR，1.08；95% CI，0.89-1.32；P = .42；P 表示相互作用= .10)，此外，在新发 HF 或 WHF 中，托拉塞米与呋塞米策略在住院治疗、首次全因住院治疗或 12 个月总住院治疗方面没有显着差异。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：在因心力衰竭住院后出院的患者中，与 WHF 相比，新发心力衰竭具有更好的临床和患者报告结果。无论心衰类型如何，托拉塞米和呋塞米在 12 个月的临床或患者报告的结果方面没有显着差异。</p><p style="color: lightgray">电话号码： <a href="https://pubmed.ncbi.nlm.nih.gov/37955908/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114050918&v=2.17.9.post6+86293ac">37955908</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.4776>10.1001/jamacardio.2023.4776</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37955908</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>塞利姆·克里姆</dc:creator><dc:creator>森希尔·阿南德</dc:creator><dc:creator>斯蒂芬·J·格林</dc:creator><dc:creator>陈安琪</dc:creator><dc:creator>丹尼尔·沃伊迪拉</dc:creator><dc:creator>胡安·维拉罗</dc:creator><dc:creator>赫伯特·霍特</dc:creator><dc:creator>约翰·M·赫尔</dc:creator><dc:creator>埃里克·爱森斯坦</dc:creator><dc:creator>凯文·J·安斯特罗姆</dc:creator><dc:creator>伯特伦·皮特</dc:creator><dc:creator>埃里克·委拉斯开兹</dc:creator><dc:creator>罗伯特·J·门茨</dc:creator><dc:date>2023-11-13</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>托塞米与呋塞米在新发慢性心力衰竭患者与恶化慢性心力衰竭患者中的​​比较：TRANSFORM-HF 随机临床试验的子研究</dc:title><dc:identifier>下午:37955908</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.4776</dc:identifier></item><item><title>美国的社区环境负担和心血管健康</title><link/>https://pubmed.ncbi.nlm.nih.gov/37955891/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff= 20231114050918&amp;v=2.17.9.post6+86293ac<description>结论和相关性：在这项针对美国社区的横断面研究中，累积环境负担与较高的心血管危险因素和疾病发生率相关，尽管绝对差异很小。在社会弱势社区中观察到最强的关联。解决恶劣环境条件的举措是否会改善心血管健康需要更多的前瞻性研究。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA 心脏。 2023 年 11 月 13 日。doi：10.1001/jamacardio.2023.4680。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：心血管疾病是美国的首要死因。然而，人们对美国社区累积环境负担与心血管健康之间的关系知之甚少。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：评估社区环境负担与心血管危险因素和疾病患病率的总体关系以及社会脆弱性水平的关系。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、设置和参与者：这是一项针对 71 659 个美国人口普查区的全国横断面研究。美国疾病控制和预防中心 (CDC) 以及有毒物质和疾病登记局的环境负担 (EBI) 和社会脆弱性指数与 2020 年 CDC PLACES 数据集相关联。数据分析时间为 2023 年 3 月至 10 月。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">暴露：EBI，衡量累积环境负担的指标，涵盖 5 个领域（空气污染、危险或有毒场所、建筑环境、交通基础设施和水污染）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和指标：心血管危险因素（高血压、糖尿病和肥胖）和心血管疾病（冠心病和中风）的社区患病率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在美国各地，环境负担最高的社区（EBI 顶部四分位数）比环境负担最低的社区（EBI 底部四分位数）更有可能位于城市（16 626 [92.7%] vs 13 414 [75.4%]）中西部地区（5191 [28.9%] vs 2782 [15.6%]）的社会脆弱性得分中位数（IQR）较高（0.64 [0.36-0.85] vs 0.42 [0.20-0.65]），并且成年人的比例较高种族或民族少数群体（中位数 [IQR]，34% [12-73] vs 12% [5-30]）。调整后，环境负担最高的社区的心血管危险因素发生率显着高于环境负担最低的社区，包括高血压（平均[SD]，32.83%[7.99] vs 32.14%[6.99]；调整后差异，0.84%； 95% CI，0.71-0.98）、糖尿病（平均 [SD]，12.19% [4.33] vs 10.68% [3.27]；调整后差异，0.62%；95% CI，0.53-0.70）和肥胖（平均 [SD] ，33.57% [7.62] vs 30.86% [6.15]；调整后差异，0.77%；95% CI，0.60-0.94）。同样，环境负担最高的社区冠心病（平均[SD]，6.66% [2.15] vs 6.82% [2.41]；调整后差异，0.28%；95% CI，0.22-0.33）和中风的发病率显着较高（平均值 [SD]，3.65% [1.47] vs 3.31% [1.12]；调整后差异，0.19%；95% CI，0.15-0.22）。在地理空间上匹配环境负担最高和最低的社区并基于其他协变量后，结果是一致的。环境负担四分位数与心血管危险因素和疾病之间的关联在社会弱势社区中最为明显。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：在这项针对美国社区的横断面研究中，累积环境负担与较高的心血管危险因素和疾病发生率相关，尽管绝对差异很小。在社会弱势社区中观察到最强的关联。解决恶劣环境条件的举措是否会改善心血管健康需要更多的前瞻性研究。</p><p style="color: lightgray">电话号码： <a href="https://pubmed.ncbi.nlm.nih.gov/37955891/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114050918&v=2.17.9.post6+86293ac">37955891</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.4680>10.1001/jamacardio.2023.4680</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37955891</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>迈克尔·刘</dc:creator><dc:creator>维沙尔·R·帕特尔</dc:creator><dc:creator>蕾妮·萨拉斯</dc:creator><dc:creator>玛丽·B·赖斯</dc:creator><dc:creator>德鲁夫·卡齐</dc:creator><dc:creator>郑兆年</dc:creator><dc:creator>里希·K·瓦德拉</dc:creator><dc:date>2023-11-13</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>美国的社区环境负担和心血管健康</dc:title><dc:identifier>下午:37955891</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.4680</dc:identifier></item><item><title>优先考虑暴露组以减轻心血管疾病负担</title><link/>https://pubmed.ncbi.nlm.nih.gov/37955872/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff= 20231114050918&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA 心脏。 2023 年 11 月 13 日。doi：10.1001/jamacardio.2023.4722。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">电话号码： <a href="https://pubmed.ncbi.nlm.nih.gov/37955872/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114050918&v=2.17.9.post6+86293ac">37955872</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.4722>10.1001/jamacardio.2023.4722</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37955872</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>艾丽卡·S·斯帕茨</dc:creator><dc:creator>陈凯</dc:creator><dc:creator>哈伦·M·克鲁霍尔兹</dc:creator><dc:date>2023-11-13</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>优先考虑暴露组以减轻心血管疾病负担</dc:title><dc:identifier>下午：37955872</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.4722</dc:identifier></item><item><title>射血分数降低的心力衰竭患者的体力活动：增加容量</title><link/>https://pubmed.ncbi.nlm.nih.gov/37955620/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff= 20231114050918&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。 2023 年 11 月 13 日。doi：10.1161/CIRCULATIONAHA.123.067588。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">电话号码： <a href="https://pubmed.ncbi.nlm.nih.gov/37955620/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114050918&v=2.17.9.post6+86293ac">37955620</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067588>10.1161/流通AHA.123.067588</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37955620</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>大卫·J·惠兰</dc:creator><dc:date>2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>射血分数降低的心力衰竭患者的体力活动：增加容量</dc:title><dc:identifier>下午:37955620</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.067588</dc:identifier></item><item><title>对射血分数降低的心力衰竭患者进行生活方式步行干预：WATCHFUL 试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37955615/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff= 20231114050918&amp;v=2.17.9.post6+86293ac<description>背景：身体活动对于治疗射血分数降低的心力衰竭（HFrEF）至关重要，而融入日常生活的步行是这种身体活动的特别合适的形式。本研究旨在确定与常规护理相比，结合自我监测和定期电话咨询的 6 个月生活方式步行干预是否可以改善稳定的 HFrEF 患者通过六分钟步行测试 (6MWT) 评估的功能能力。方法：WATCHFUL 试验是... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。 2023 年 11 月 13 日。doi：10.1161/CIRCULATIONAHA.123.067395。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>身体活动对于治疗射血分数降低的心力衰竭（HFrEF）至关重要，而融入日常生活的步行是这种身体活动的特别合适的形式。本研究旨在确定与常规护理相比，结合自我监测和定期电话咨询的 6 个月生活方式步行干预是否可以改善稳定的 HFrEF 患者通过六分钟步行测试 (6MWT) 评估的功能能力。<b>方法：</b> WATCHFUL 试验是一项为期 6 个月的多中心、平行组、随机、对照试验，招募了来自六个捷克心血管中心的 HFrEF 患者。符合资格的参与者年龄≥18岁，左心室射血分数&lt;40%，有NYHA II/III级症状，正在接受指南推荐的药物治疗，不包括基线6MWT超过450m的参与者。干预组的患者配备了 Garmin vívofit 活动追踪器，并每月接受研究护士的电话咨询，鼓励他们采用自我监控、目标设定和行动计划等行为改变技术来增加每日步数。对照组患者继续常规护理。主要结果是 6 个月时 6MWT 期间各组行走距离（以米为单位）的差异。次要结果包括通过髋部佩戴的 Actigraph wGT3X-BT 加速计测量的每日步数和中度至剧烈体力活动分钟数 (MVPA)、NT-proBNP 和 hsCRP 生物标志物、射血分数、人体测量指标、抑郁评分、自我评估疗效、生活质量和生存风险评分。主要分析是通过意向治疗进行的。<b>结果：</b>从 218 名筛查患者中，202 名患者被随机分配（65 岁；22.8% 女性；90.6% NYHA II；左心室射血分数 32.5%；6MWT 385m；5071 步/天；每天 10.9 分钟 MVPA）。六个月时，6MWT 未检测到组间差异（7.4 m，95% CI -8.0 至 22.7，p=0.345，N=186）。与对照组相比，干预组的平均每日步数增加了 1420 步（95% CI：749；2091），每日 MVPA 分钟数增加了 8.2 分钟（95% CI：3.0；13.3）。没有检测到任何其他次要结果的组间差异。<b>结论：</b>虽然 HFrEF 患者的生活方式干预使每日步数提高了约 25%，但未能证明功能能力有相应的改善。需要进一步的研究来了解增加体力活动和功能结果之间的脱节。</p><p style="color: lightgray">电话号码： <a href="https://pubmed.ncbi.nlm.nih.gov/37955615/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114050918&v=2.17.9.post6+86293ac">37955615</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067395>10.1161/流通AHA.123.067395</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37955615</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>托马斯·维特洛夫斯基</dc:creator><dc:creator>米哈尔·西拉内克</dc:creator><dc:creator>特蕾莎·弗莱博娃</dc:creator><dc:creator>尤利安·甘特</dc:creator><dc:creator>伊维塔·斯沃博多娃</dc:creator><dc:creator>阿莱斯·林哈特</dc:creator><dc:creator>伊里·帕雷尼卡</dc:creator><dc:creator>玛丽·米克利科娃</dc:creator><dc:creator>伦卡·苏亚科娃</dc:creator><dc:creator>大卫·波斯皮希尔</dc:creator><dc:creator>拉德克·佩卢什</dc:creator><dc:creator>丹妮拉·奥德拉兹科娃</dc:creator><dc:creator>彼得·帕里泽克</dc:creator><dc:creator>简·普雷切克</dc:creator><dc:creator>马丁·胡提拉</dc:creator><dc:creator>米洛斯·塔博斯基</dc:creator><dc:creator>吉里·维斯利</dc:creator><dc:creator>马丁·格里瓦</dc:creator><dc:creator>米罗斯拉夫·塞梅拉德</dc:creator><dc:creator>瓦茨拉夫邦克</dc:creator><dc:creator>卡罗琳娜·赫拉布科娃</dc:creator><dc:creator>阿德拉·沃伊库夫科娃</dc:creator><dc:creator>米哈尔·斯沃博达</dc:creator><dc:creator>扬·贝洛拉维克</dc:creator><dc:creator>警惕的调查人员</dc:creator><dc:date>2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>对射血分数降低的心力衰竭患者进行生活方式步行干预：WATCHFUL 试验</dc:title><dc:identifier>下午:37955615</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.067395</dc:identifier></item><item><title>美国大学体育协会运动员的心脏性猝死：一项为期 20 年的研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37955565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff= 20231114050918&amp;v=2.17.9.post6+86293ac<description>背景：了解年轻竞技运动员心源性猝死（SCD）的发病率、原因和趋势对于制定预防政策至关重要。方法：本研究纳入了 20 年期间（2002 年 7 月 1 日至 2022 年 6 月 30 日）期间美国大学体育协会运动员的死亡情况。运动员死亡是通过 4 个独立的数据库和搜索策略（国家大学体育协会决议列表、家长心脏观察数据库……）确定的。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。 2023 年 11 月 13 日。doi：10.1161/CIRCULATIONAHA.123.065908。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>了解年轻竞技运动员心源性猝死（SCD）的发病率、原因和趋势对于制定预防政策至关重要。<b>方法：</b>本研究纳入了 20 年期间（2002 年 7 月 1 日至 2022 年 6 月 30 日）期间美国大学体育协会运动员的死亡情况。运动员死亡是通过 4 个独立的数据库和搜索策略（国家大学体育协会决议清单、家长心脏观察数据库和媒体报道、国家灾难性运动损伤研究中心数据库和保险索赔）来确定的。 Autopsy reports and medical history were reviewed by an expert panel to adjudicate causes of SCD. <b>Results:</b> A total of 143 SCD cases in National Collegiate Athletic Association athletes were identified from 1102 total deaths. The National Collegiate Athletic Association resolutions list identified 117 of 143 (82%), the Parent Heart Watch database or media reports identified 89 of 143 (62%), the National Center for Catastrophic Sports Injury Research database identified 63 of 143 (44%), and insurance claims identified 27 of 143 (19%) SCD cases. The overall incidence of SCD was 1:63682 athlete-years (95% CI, 1:54065-1:75010). Incidence was higher in male athletes than in female athletes (1:43348 [95% CI, 1:36228-1:51867] versus 1:164504 [95% CI, 1:110552-1:244787] athlete-years, respectively) and Black athletes compared with White athletes (1:26704 [1:20417-1:34925] versus 1:74581 [1:60247-1:92326] athlete-years, respectively). The highest incidence of SCD was among Division I male basketball players (1:8188 [White, 1:5848; Black, 1:7696 athlete-years]). The incidence rate for SCD decreased over the study period (5-year incidence rate ratio, 0.71 [95% CI, 0.61-0.82]), whereas the rate of noncardiovascular deaths remained stable (5-year incidence rate ratio, 0.98 [95% CI, 0.94-1.04]). Autopsy-negative sudden unexplained death (19.5%) was the most common postmortem examination finding, followed by idiopathic left ventricular hypertrophy or possible cardiomyopathy (16.9%) and hypertrophic cardiomyopathy (12.7%), in cases with enough information for adjudication (118 of 143). Eight cases of death were attributable to myocarditis over the study period (1 case from January 1, 2020, through June 30, 2022), with none attributed to COVID-19 infection. SCD events were exertional in 50% of cases. Exertional SCD was more common among those with coronary artery anomalies (100%) and arrhythmogenic cardiomyopathy (83%). <b>Conclusions:</b> The incidence of SCD in college athletes has decreased. Male sex, Black race, and basketball are associated with a higher incidence of SCD.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37955565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114050918&v=2.17.9.post6+86293ac">37955565</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065908>10.1161/CIRCULATIONAHA.123.065908</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37955565</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Bradley J Petek</dc:creator><dc:creator> Timothy W Churchill</dc:creator><dc:creator> Nathaniel Moulson</dc:creator><dc:creator> Stephanie A Kliethermes</dc:creator><dc:creator> Aaron L Baggish</dc:creator><dc:creator> Jonathan A Drezner</dc:creator><dc:creator> Manesh R Patel</dc:creator><dc:creator> Michael J Ackerman</dc:creator><dc:creator> Kristen L Kucera</dc:creator><dc:creator> David M Siebert</dc:creator><dc:creator> Lauren Salerno</dc:creator><dc:creator> Monica Zigman Suchsland</dc:creator><dc:creator> Irfan M Asif</dc:creator><dc:creator> Joseph J Maleszewski</dc:creator><dc:creator> Kimberly G Harmon</dc:creator><dc:date> 2023-11-13</dc:date><dc:source> Circulation</dc:source><dc:title> Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A 20-Year Study</dc:title><dc:identifier> pmid:37955565</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.065908</dc:identifier></item><item><title> Declining Risk of Sudden Cardiac Death in Young Athletes</title><link/> https://pubmed.ncbi.nlm.nih.gov/37955558/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114050918&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067243. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37955558/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114050918&v=2.17.9.post6+86293ac">37955558</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067243>10.1161/CIRCULATIONAHA.123.067243</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37955558</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Domenico Corrado</dc:creator><dc:creator> Alessandro Zorzi</dc:creator><dc:date> 2023-11-13</dc:date><dc:source> Circulation</dc:source><dc:title> Declining Risk of Sudden Cardiac Death in Young Athletes</dc:title><dc:identifier> pmid:37955558</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.067243</dc:identifier></item><item><title> Cyclin D-CDK4 Disulfide Bond Attenuates Pulmonary Vascular Cell Proliferation</title><link/> https://pubmed.ncbi.nlm.nih.gov/37955182/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114050918&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: A novel disulfide bond in cyclin D-CDK4 acts as a rapid switch to inhibit kinase activity and halt cell proliferation. This oxidative modification forms at a critical cysteine residue, which is unique to CDK4, offering the potential for the design of a selective covalent inhibitor predicted to be beneficial in PH. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 Nov 13. doi: 10.1161/CIRCRESAHA.122.321836. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Pulmonary hypertension (PH) is a chronic vascular disease characterized, among other abnormalities, by hyperproliferative smooth muscle cells and a perturbed cellular redox and metabolic balance. Oxidants induce cell cycle arrest to halt proliferation; however, little is known about the redox-regulated effector proteins that mediate these processes. Here, we report a novel kinase-inhibitory disulfide bond in cyclin D-CDK4 (cyclin-dependent kinase 4) and investigate its role in cell proliferation and PH. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Oxidative modifications of cyclin D-CDK4 were detected in human pulmonary arterial smooth muscle cells and human pulmonary arterial endothelial cells. Site-directed mutagenesis, tandem mass-spectrometry, cell-based experiments, in vitro kinase activity assays, in silico structural modeling, and a novel redox-dead constitutive knock-in mouse were utilized to investigate the nature and definitively establish the importance of CDK4 cysteine modification in pulmonary vascular cell proliferation. Furthermore, the cyclin D-CDK4 oxidation was assessed in vivo in the pulmonary arteries and isolated human pulmonary arterial smooth muscle cells of patients with pulmonary arterial hypertension and in 3 preclinical models of PH. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Cyclin D-CDK4 forms a reversible oxidant-induced heterodimeric disulfide dimer between C7/8 and C135, respectively, in cells in vitro and in pulmonary arteries in vivo to inhibit cyclin D-CDK4 kinase activity, decrease Rb (retinoblastoma) protein phosphorylation, and induce cell cycle arrest. Mutation of CDK4 C135 causes a kinase-impaired phenotype, which decreases cell proliferation rate and alleviates disease phenotype in an experimental mouse PH model, suggesting this cysteine is indispensable for cyclin D-CDK4 kinase activity. Pulmonary arteries and human pulmonary arterial smooth muscle cells from patients with pulmonary arterial hypertension display a decreased level of CDK4 disulfide, consistent with CDK4 being hyperactive in human pulmonary arterial hypertension. Furthermore, auranofin treatment, which induces the cyclin D-CDK4 disulfide, attenuates disease severity in experimental PH models by mitigating pulmonary vascular remodeling. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: A novel disulfide bond in cyclin D-CDK4 acts as a rapid switch to inhibit kinase activity and halt cell proliferation. This oxidative modification forms at a critical cysteine residue, which is unique to CDK4, offering the potential for the design of a selective covalent inhibitor predicted to be beneficial in PH.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37955182/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114050918&v=2.17.9.post6+86293ac">37955182</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.122.321836>10.1161/CIRCRESAHA.122.321836</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37955182</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Hannah Knight</dc:creator><dc:creator> Giancarlo Abis</dc:creator><dc:creator> Manpreet Kaur</dc:creator><dc:creator> Hannah LH Green</dc:creator><dc:creator> Susanne Krasemann</dc:creator><dc:creator> Kristin Hartmann</dc:creator><dc:creator> Steven Lynham</dc:creator><dc:creator> James Clark</dc:creator><dc:creator> Lan Zhao</dc:creator><dc:creator> Clemens Ruppert</dc:creator><dc:creator> Astrid Weiss</dc:creator><dc:creator> Ralph T Schermuly</dc:creator><dc:creator> Philip Eaton</dc:creator><dc:creator> Olena Rudyk</dc:creator><dc:date> 2023-11-13</dc:date><dc:source> Circulation research</dc:source><dc:title> Cyclin D-CDK4 Disulfide Bond Attenuates Pulmonary Vascular Cell Proliferation</dc:title><dc:identifier> pmid:37955182</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.122.321836</dc:identifier></item><item><title> DWORF Extends Life Span in a PLN-R14del Cardiomyopathy Mouse Model by Reducing Abnormal Sarcoplasmic Reticulum Clusters</title><link/> https://pubmed.ncbi.nlm.nih.gov/37955153/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114050918&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Disorganized S/ER is a major characteristic of PLN-R14del cardiomyopathy in humans and mice and results in cardiomyocyte death. DWORF overexpression delayed PLN-R14del cardiomyopathy progression and extended life span in R14^(Δ/Δ) mice, by reducing abnormal S/ER clusters. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 Nov 13. doi: 10.1161/CIRCRESAHA.123.323304. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: The p.Arg14del variant of the <i>PLN</i> (phospholamban) gene causes cardiomyopathy, leading to severe heart failure. Calcium handling defects and perinuclear PLN aggregation have both been suggested as pathological drivers of this disease. Dwarf open reading frame (DWORF) has been shown to counteract PLN regulatory calcium handling function in the sarco/endoplasmic reticulum (S/ER). Here, we investigated the potential disease-modulating action of DWORF in this cardiomyopathy and its effects on calcium handling and PLN aggregation. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We studied a PLN-R14del mouse model, which develops cardiomyopathy with similar characteristics as human patients, and explored whether cardiac DWORF overexpression could delay cardiac deterioration. To this end, R14 <sup>Δ/Δ</sup> (homozygous PLN-R14del) mice carrying the DWORF transgene (R14 <sup>Δ/Δ</sup> DWORF <sup>Tg</sup> [R14 <sup>Δ/Δ</sup> mice with a copy of the DWORF transgene]) were used. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: DWORF expression was suppressed in hearts of R14 <sup>Δ/Δ</sup> mice with severe heart failure. Restoration of DWORF expression in R14 <sup>Δ/Δ</sup> mice delayed cardiac fibrosis and heart failure and increased life span >;2-fold (from 8 to 18 weeks). DWORF accelerated sarcoplasmic reticulum calcium reuptake and relaxation in isolated cardiomyocytes with wild-type PLN, but in R14 <sup>Δ/Δ</sup> cardiomyocytes, sarcoplasmic reticulum calcium reuptake and relaxation were already enhanced, and no differences were detected between R14 <sup>Δ/Δ</sup> and R14 <sup>Δ/Δ</sup> DWORF <sup>Tg</sup> . Rather, DWORF overexpression delayed the appearance and formation of large pathogenic perinuclear PLN clusters. Careful examination revealed colocalization of sarcoplasmic reticulum markers with these PLN clusters in both R14 <sup>Δ/Δ</sup> mice and human p.Arg14del PLN heart tissue, and hence these previously termed aggregates are comprised of abnormal organized S/ER. This abnormal S/ER organization in PLN-R14del cardiomyopathy contributes to cardiomyocyte cell loss and replacement fibrosis, consequently resulting in cardiac dysfunction. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Disorganized S/ER is a major characteristic of PLN-R14del cardiomyopathy in humans and mice and results in cardiomyocyte death. DWORF overexpression delayed PLN-R14del cardiomyopathy progression and extended life span in R14 <sup>Δ/Δ</sup> mice, by reducing abnormal S/ER clusters.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37955153/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114050918&v=2.17.9.post6+86293ac">37955153</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.123.323304>10.1161/CIRCRESAHA.123.323304</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37955153</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Nienke M Stege</dc:creator><dc:creator> Tim R Eijgenraam</dc:creator><dc:creator> Vivian Oliveira Nunes Teixeira</dc:creator><dc:creator> Anna M Feringa</dc:creator><dc:creator> Elisabeth M Schouten</dc:creator><dc:creator> Diederik WD Kuster</dc:creator><dc:creator> Jolanda van der Velden</dc:creator><dc:creator> Anouk HG Wolters</dc:creator><dc:creator> Ben NG Giepmans</dc:creator><dc:creator> Catherine A Makarewich</dc:creator><dc:creator> Rhonda Bassel-Duby</dc:creator><dc:creator> Eric N Olson</dc:creator><dc:creator> Rudolf A de Boer</dc:creator><dc:creator> Herman HW Silljé</dc:creator><dc:date> 2023-11-13</dc:date><dc:source> Circulation research</dc:source><dc:title> DWORF Extends Life Span in a PLN-R14del Cardiomyopathy Mouse Model by Reducing Abnormal Sarcoplasmic Reticulum Clusters</dc:title><dc:identifier> pmid:37955153</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323304</dc:identifier></item><item><title> NAT10 Is Involved in Cardiac Remodeling Through ac4C-Mediated Transcriptomic Regulation</title><link/> https://pubmed.ncbi.nlm.nih.gov/37955115/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114050918&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Therefore, our data suggest that modulating epitranscriptomic processes, such as ac4C acetylation through NAT10, may be a promising therapeutic target against cardiac remodeling. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 Nov 13. doi: 10.1161/CIRCRESAHA.122.322244. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Heart failure, characterized by cardiac remodeling, is associated with abnormal epigenetic processes and aberrant gene expression. Here, we aimed to elucidate the effects and mechanisms of NAT10 (N-acetyltransferase 10)-mediated N4-acetylcytidine (ac4C) acetylation during cardiac remodeling. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: NAT10 and ac4C expression were detected in both human and mouse subjects with cardiac remodeling through multiple assays. Subsequently, acetylated RNA immunoprecipitation and sequencing, thiol (SH)-linked alkylation for the metabolic sequencing of RNA (SLAM-seq), and ribosome sequencing (Ribo-seq) were employed to elucidate the role of ac4C-modified posttranscriptional regulation in cardiac remodeling. Additionally, functional experiments involving the overexpression or knockdown of NAT10 were conducted in mice models challenged with Ang II (angiotensin II) and transverse aortic constriction. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: NAT10 expression and RNA ac4C levels were increased in in vitro and in vivo cardiac remodeling models, as well as in patients with cardiac hypertrophy. Silencing and inhibiting NAT10 attenuated Ang II-induced cardiomyocyte hypertrophy and cardiofibroblast activation. Next-generation sequencing revealed ac4C changes in both mice and humans with cardiac hypertrophy were associated with changes in global mRNA abundance, stability, and translation efficiency. Mechanistically, NAT10 could enhance the stability and translation efficiency of <i>CD47</i> and <i>ROCK2</i> transcripts by upregulating their mRNA ac4C modification, thereby resulting in an increase in their protein expression during cardiac remodeling. Furthermore, the administration of Remodelin, a NAT10 inhibitor, has been shown to prevent cardiac functional impairments in mice subjected to transverse aortic constriction by suppressing cardiac fibrosis, hypertrophy, and inflammatory responses, while also regulating the expression levels of CD47 and ROCK2. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Therefore, our data suggest that modulating epitranscriptomic processes, such as ac4C acetylation through NAT10, may be a promising therapeutic target against cardiac remodeling.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37955115/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114050918&v=2.17.9.post6+86293ac">37955115</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.122.322244>10.1161/CIRCRESAHA.122.322244</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37955115</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Jing Shi</dc:creator><dc:creator> Chuanxi Yang</dc:creator><dc:creator> Kun Zhao</dc:creator><dc:creator> Jing Zhang</dc:creator><dc:creator> Peng Li</dc:creator><dc:creator> Chuiyu Kong</dc:creator><dc:creator> Xiaoguang Wu</dc:creator><dc:creator> Haoliang Sun</dc:creator><dc:creator> Rui Zheng</dc:creator><dc:creator> Wei Sun</dc:creator><dc:creator> Lianmin Chen</dc:creator><dc:creator> Xiangqing Kong</dc:creator><dc:date> 2023-11-13</dc:date><dc:source> Circulation research</dc:source><dc:title> NAT10 Is Involved in Cardiac Remodeling Through ac4C-Mediated Transcriptomic Regulation</dc:title><dc:identifier> pmid:37955115</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.122.322244</dc:identifier></item></channel></rss>